Erudio Healtherudio.com
Sponsor
Telix Pharmaceuticals (Innovations) trials: what clinicians said in public
No HCP commentary report on a trial sponsored by Telix Pharmaceuticals (Innovations) yet. Erudio has found public clinician commentary on 3 clinical trials sponsored by Telix Pharmaceuticals (Innovations): NCT04876651, ProstACT Global and ProstACT SELECT. Each trial's page lists the podcasts, videos and posts found so far and the price of a report.
Listed by lead sponsor as registered on ClinicalTrials.gov (Telix Pharmaceuticals (Innovations) Pty Limited; Telix Pharmaceuticals (Innovations) Pty Ltd). A trial led by a partner or a research group is on that sponsor's page. Only trials with public clinician commentary found are listed, not every trial the sponsor runs.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| NCT04876651 NCT04876651 · Telix Pharmaceuticals (Innovations) Pty Ltd FocusedView → | PSMA-expressing metastatic castration-resistant prostate cancer | Phase 3 | Focused | View | |||
| ProstACT SELECT NCT04786847 · Telix Pharmaceuticals (Innovations) Pty Limited FocusedView → | PSMA-expressing metastatic castration-resistant prostate cancer | Phase 1 | Focused | View | |||
| ProstACT Global NCT06520345 · Telix Pharmaceuticals (Innovations) Pty Limited FocusedView → | PSMA-positive metastatic castration-resistant prostate cancer after ARPI | Phase 3 | Focused | View | |||